What is the current stock price of argenx SE (ARGX)?

As of the latest market data, argenx SE (ARGX) is trading at $799.65. The stock has seen a loss of -0.11% today.

Does argenx SE (ARGX) pay a dividend?

Based on current data, argenx SE does not have a confirmed active dividend policy.

What is the market cap of argenx SE?

The current market capitalization of argenx SE (ARGX) is approximately unavailable.

ARGX

argenx SE·Healthcare

799.65

0.106%(−0.85)

Market Closed

845.00

5.671%(+45.35)

After Hours

Last Updated: — ET

52W L: $510.0652W H: $934.62

ARGX NEWS

defenseworld.net

6d ago

SG Americas Securities LLC Has $2.67 Million Stock Holdings in argenex SE $ARGX

SG Americas Securities LLC increased its stake in argenex SE (NASDAQ: ARGX) by 94.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,179 shares of the company's stock after purchasing an additional 1,548 shares during the period. SG Americas Securities LLC's holdings in

defenseworld.net

Mar 31

Allspring Global Investments Holdings LLC Sells 38,598 Shares of argenex SE $ARGX

Allspring Global Investments Holdings LLC trimmed its position in shares of argenex SE (NASDAQ: ARGX) by 18.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 172,732 shares of the company's stock after selling 38,598 shares during the quarter. Allspring Global Investments

zacks.com

Mar 24

CSLLY or ARGX: Which Is the Better Value Stock Right Now?

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both CSL Limited Sponsored ADR (CSLLY) and argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks?

businesswire.com

Mar 24

eClinical Solutions elluminate® Platform Supports argenx to Enhance Data Oversight and Efficiency

BOSTON--(BUSINESS WIRE)--eClinical Solutions LLC, a global provider of digital clinical software and services, today announced that argenx SE, a global immunology company, is expanding adoption of the elluminate Clinical Data Cloud® to improve and enhance clinical data processes. The elluminate platform is designed to improve access to and analysis of clinical trial data across sources with a central source of communication for clinical data, including Data Central for collaborative data review.

zacks.com

Mar 23

CSLLY vs. ARGX: Which Stock Is the Better Value Option?

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either CSL Limited Sponsored ADR (CSLLY) or argenex SE (ARGX). But which of these two stocks is more attractive to value investors?

defenseworld.net

Mar 15

Alkeon Capital Management LLC Grows Stock Position in argenex SE $ARGX

Alkeon Capital Management LLC grew its holdings in argenex SE (NASDAQ: ARGX) by 133.3% in the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 175,000 shares of the company's stock after acquiring an additional 100,000 shares during the quarter. Alkeon Capital

Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Sector

Healthcare

Industry

Biotechnology

Employees

1,599

IPO Date

2017-05-18

Beta

-0.09

Websitewww.argenx.com↗